Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time

July 14, 2020

LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Company's next steps.

To access the conference call, interested parties may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978 (International/Toll) 10 minutes before the call is scheduled to begin using the Conference ID 1879551. The conference call will be webcast via the Investors page on the Company's website at https://investor.celsion.com/. The call will be archived for replay through July 29, 2020. The replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID 1879551. Approximately two hours following the live event, an audio replay of the conference call will also be available on the Company's website for 90 days.

About Celsion Corporation

Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company's product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit: http://www.celsion.com. (CLSN-FIN).

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact
Jeffrey W. Church
Executive Vice President & CFO
609-482-2455
jchurch@celsion.com

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #

Source: Celsion CORP